2025 年核酸药物品牌推荐 技术迭代浪潮下的创新领航者 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 核酸药物定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 3 | | 2.1 市场规模 | 3 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 5 | | 3.3 十大品牌推荐 | 5 | | 四、发展趋势 | 7 | | 4.1 技术突破驱动：肝外递送与 AI 设计引领创新浪潮 | 7 | | 4.2 商业化加速：License-out 与医保支付共促市场扩容 | 7 | | 4.3 政策与资本双轮驱动：全链条支持构建产业生态 | 7 | | 4.4 适应症拓展：从罕见病向慢性病与肿瘤领域渗透 | 8 | 2025 年核酸药物品牌推荐 一、市场背景 1.1 摘要 2018 年，全球第一款 siRNA 药物 Patisiran 获批，推动了整个行业向广角度治疗领域扩 张。仅在 2018 至 2020 年间，就有 4 款 siRNA 药物和 3 ...

【siRNA药物行业深度：黎明已至，国产争先】 siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已 成为新药开发热门方向。 技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是目前的突破重心，技术路径包括LNP、抗体、 肽类以及VLP递送，各有优劣，其中AOC发展稍快。 【siRNA药物行业深度：黎明已至，国产争先】 siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已 成为新药开发热门方向。 技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是目前的突破重心，技术路径包括LNP、抗体、 肽类以及VLP递送，各有优劣，其中AOC发展稍快。 siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已成为肝递送 的"标准答案"，其他海外巨头如Arrowhead和Dicerna等针对PCSK9、AGT、Lp(a)以及ApoC3等心血管常见靶点的 siRNA药物已进入 ...

siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已 成为肝递送的"标准答案"，其他海外巨头如Arrowhead和Dicerna等针对PCSK9、AGT、Lp(a)以及ApoC3 等心血管常见靶点的siRNA药物已进入临床后期或商业化的收获期，而针对肌肉、神经系统以及眼部等 肝外器官目前仍处于研发早期阶段，目前Alnylam的C16递送平台已在CNS领域、Arrowhead的TRiM平 台在脂肪组织领域初步展现潜力，未来新靶点的发现与肝外递送平台将成为竞争的核心要点。 智通财经APP获悉，中邮证券发布研报称，siRNA药物可精准沉默致病蛋白，优势显著，递送系统为核 心技术。海外巨头基于GalNAc肝递送平台，针对心血管靶点的药物已进入收获期。国内企业百花齐 放，成为全球重要参与者，与MNC合作频发。 中邮证券主要观点如下： siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间 长，目前已成为新药开发热门方向。技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是 目前 ...

证券研究报告 ➢ siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。 技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是目前的突破重心，技术路径包括LNP、抗体、肽类以及VLP递送，各有优劣， 其中AOC发展稍快。 ➢ 海外巨头渐入收获期，静待肝外递送POC 黎明已至，国产争先 ——siRNA药物行业深度报告 行业投资评级：强大于市|维持 盛丽华/陈灿 中邮证券研究所 医药生物团队 中邮证券 1 1 发布时间：2026-02-27 投资要点 siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已成为肝递送的"标准答案"，其他海 外巨头如Arrowhead和Dicerna等针对PCSK9、AGT、Lp(a)以及ApoC3等心血管常见靶点的siRNA药物已进入临床后期或商业化的收获期，而 针对肌肉、神经系统以及眼部等肝外器官目前仍处于研发早期阶段，目前Alnylam的C16递送平台已在CNS领域、Arrowhead的TRiM平台在脂 肪 ...

Core Insights - Vir Biotechnology has announced significant partnerships and advancements in its pipeline, including a global collaboration with Astellas and promising Phase 1 data for its oncology program VIR-5500, which targets hard-to-treat cancers [2][4]. Pipeline Programs - The company is advancing several investigational therapies, including VIR-5500 for metastatic castration-resistant prostate cancer (mCRPC), with positive Phase 1 data indicating dose-dependent anti-tumor activity [4][7]. - The Phase 1 study of VIR-5818, targeting HER2, is ongoing, with response data expected in the second half of 2026 [4]. - The Phase 1 study of VIR-5525, targeting EGFR, continues to enroll participants as planned [5]. Chronic Hepatitis Delta (CHD) Program - Vir Biotechnology has licensed to Norgine the combination of tobevibart and elebsiran for treating CHD, aiming to reach patients globally [2][7]. - Phase 2 SOLSTICE data showed that the combination therapy achieved undetectable hepatitis delta virus RNA in 88% of participants at Week 96 [7]. - The ECLIPSE registrational program is designed to evaluate the safety and efficacy of tobevibart and elebsiran, with topline data from ECLIPSE 1 expected in Q4 2026 and from ECLIPSE 2 and 3 in Q1 2027 [21]. Financial Results - As of December 31, 2025, the company reported approximately $781.6 million in cash, cash equivalents, and investments, a decline of $29.1 million in Q4 2025 [9]. - Revenue for Q4 2025 was $64.1 million, a significant increase from $12.4 million in Q4 2024, primarily due to a $64.3 million license revenue from the Norgine agreement [10]. - The net loss for Q4 2025 was $(42.9) million, an improvement from a net loss of $(104.6) million in Q4 2024 [17]. Future Outlook - The company expects its cash reserves to fund operations into the second quarter of 2028, bolstered by the Astellas collaboration and equity investment [18]. - The company plans to initiate pivotal Phase 3 trials for its oncology programs in 2027, following the expansion of dose cohorts for VIR-5500 [7][8].

Group 1: Vitality 2030 - The report highlights a significant shift in human life expectancy, indicating that while life expectancy has doubled over the past century, the growth rate has drastically slowed down, with some regions experiencing stagnation or decline [2][29]. - A new paradigm is emerging, focusing on "healthspan" rather than just lifespan, emphasizing the quality of life without severe chronic diseases, which could generate a global economic value of up to $38 trillion if healthspan is extended by just one year [2][30]. - Key technological advancements include CRISPR technology entering its 2.0 phase, with potential breakthroughs in gene therapy for cardiovascular diseases and personalized treatments for metabolic disorders [2][34][35]. Group 2: Stamina 2030 - Exoskeleton technology is evolving from medical applications to industrial and personal use, significantly enhancing human physical capabilities [3][54]. - In the medical field, exoskeletons are transitioning from mobility aids to intelligent devices that promote neurological rehabilitation, with Medicare's reimbursement policy marking a significant milestone [3][54]. - Industrial applications are showing promising results, with companies like German Bionic reporting a 75% reduction in workplace injuries after implementing exoskeleton technology [3][54]. Group 3: Brainpower 2030 - The report discusses the evolution of artificial intelligence (AI) towards general intelligence (AGI), highlighting advancements in reasoning models that can self-correct and learn from experience [6][7]. - AI is expected to enhance medical practices by significantly reducing drug development timelines from 10-15 years to just a few months, with AI-driven drug candidates already entering clinical trials [6][44]. - Brain-computer interfaces (BCIs) are advancing, with both invasive and non-invasive technologies showing promise in restoring sensory functions and translating brain activity into coherent language [9][10]. Group 4: Creativity 2030 - The integration of AI with personal creativity tools is expected to redefine individual and team productivity, with AI assistants capable of generating complex outputs like presentations and creative content [11][12]. - The emergence of "super individuals" who can independently manage product development and marketing using AI tools is reshaping the concept of team dynamics and company structures [13][14]. - Large organizations are facing challenges in adapting to the AI era, necessitating a complete overhaul of human resource practices to focus on skills and collaborative partnerships rather than traditional employment models [14][15]. Group 5: Pursuit 2030 - The report raises critical questions about individual uniqueness and decision-making in an AI-driven world, emphasizing the importance of maintaining personal judgment and growth opportunities [16][17]. - It suggests that technology amplifies not only capabilities but also choices and values, urging individuals to reflect on their direction in a rapidly evolving landscape [16][17]. - The overarching theme is the need to balance technological advancements with the preservation of human dignity and quality of life, aiming for a future where health and vitality are prioritized over mere longevity [18][51].

Core Insights - Alnylam Pharmaceuticals Inc. reported nearly $3 billion in total revenue for 2025, marking an 81% year-over-year increase, with Q4 net product revenue reaching $995 million driven by a 151% surge in the TTR franchise due to the launch of Amphotra for ATTR cardiomyopathy [1][7] - The company launched Cyreli, a new RNAi manufacturing platform aimed at expanding capacity and reducing long-term costs [2] - Alnylam provided optimistic guidance for 2026, forecasting combined net product sales between $4.9 billion and $5.3 billion, despite expecting a modest mid-single-digit decrease in net pricing for core products [2] - The internal pipeline of Alnylam includes over 25 active clinical programs, with a focus on the ACVR1C asset in the obesity space and long-term potential for products like Nrierran to enhance operating margins into the mid-40s by 2030 [3] Company Overview - Alnylam Pharmaceuticals specializes in discovering, developing, manufacturing, and commercializing therapeutics based on ribonucleic acid interference across the US, Europe, and internationally [4]

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best money-making stocks to buy right now. On February 13, Morgan Stanley trimmed the price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $360 from $408 and reiterated an Equal Weight rating, TheFly reported. In a research note, the analyst said that although near-term pressures exist, the preannounced fourth-quarter revenue and reaffirmed 2026 TTR sales guidance reflect increased confidence in the launch. On the same day, RBC Capital al ...

Core Viewpoint - Alnylam Pharmaceuticals' stock experienced a significant increase of over 6% following positive analyst notes, particularly an upgrade from Freedom Capital Markets [1][2]. Analyst Recommendations - Ilya Zubkov of Freedom Capital Markets upgraded his recommendation on Alnylam from hold to buy, while lowering the price target from $470 to $410 per share [2]. - Canaccord Genuity's Whitney Ijem also raised her price target for Alnylam from $415 to $429 per share, indicating a more bullish outlook [6]. Company Performance - Alnylam recently reported its fourth-quarter and full-year 2025 results, which disappointed investors due to a revenue miss despite a bottom-line beat [4]. - Zubkov highlighted the strong performance of Amvuttra, a drug targeting transthyretin amyloid cardiomyopathy (ATTR-CM), noting robust sales in both domestic and international markets [5]. Market Sentiment - There is a belief among some analysts that investors reacted too harshly to Alnylam's earnings release, with optimism surrounding Amvuttra's growth potential [7].

Core Viewpoint - Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is currently viewed as a strong investment opportunity despite recent price target reductions by analysts, indicating a positive long-term outlook for the company and its TTR franchise [1][2][3]. Analyst Ratings and Price Targets - Bank of America has lowered its price target for Alnylam from $529 to $462 while maintaining a Buy rating, reflecting a cautious outlook for Q4 2025 [1]. - H.C. Wainwright also reduced its price target from $570 to $510, yet continues to endorse a Buy rating, citing a disciplined approach to near-term growth and margins [2]. - Barclays initiated coverage of Alnylam with an Overweight rating and a price target of $527, part of a broader positive outlook on the biotech sector for 2026 [3]. Company Overview - Alnylam Pharmaceuticals specializes in discovering, developing, and commercializing therapeutics based on ribonucleic acid interference [4].